Welcome
Support Centre
23 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Preimplantation genetic screening for aneuploidies in patients with advanced maternal age undergoing in vitro fertilisation
ISRCTN ISRCTN76355836
ClinicalTrials.gov identifier
Public title Preimplantation genetic screening for aneuploidies in patients with advanced maternal age undergoing in vitro fertilisation
Scientific title
Acronym N/A
Serial number at source ZonMw: 945-03-013; NTR84
Study hypothesis To determine whether in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) combined with preimplantation genetic screening (PGS) in patients with advanced maternal age, i.e. women between 35 and 41 years of age, is a cost-effective alternative compared to IVF/ICSI without PGS.
Lay summary
Ethics approval Received from the local medical ethics committee
Study design Randomised, active controlled, parallel group, double blinded, multicentre trial
Countries of recruitment Netherlands
Disease/condition/study domain Subfertility, infertility
Participants - inclusion criteria 1. Women between 35 and 41 years of age
2. Undergoing IVF or ICSI
Participants - exclusion criteria Does not comply with the above inclusion criteria
Anticipated start date 01/05/2003
Anticipated end date 01/05/2006
Status of trial Completed
Patient information material
Target number of participants 372
Interventions Patients are allocated at random to one of two treatment arms:
1. IVF/ICSI with PGS (selection of embryos based on normal number of studied chromosomes), or
2. IVF/ICSI without PGS (selection of embryos based on morphology).

A maximum of two embryos will be transferred, according to the European Society of Human Reproduction and Embryology (ESHRE)-guidelines. In both treatment arms three treatment-cycles will be offered.
Primary outcome measure(s) Ongoing pregnancy rate.
Secondary outcome measure(s) 1. Time to pregnancy
2. Clinical pregnancy rate
3. Pregnancy outcome
4. Implantation rate
Sources of funding The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/pubmed/17611204
Contact name Dr  Sebastiaan  Mastenbroek
  Address Center For Reproductive Medicine
Academic Medical Center
Meibergdreef 9 (A1-229)
  City/town Amsterdam
  Zip/Postcode 1105 AZ
  Country Netherlands
  Tel +31 (0)20 566 7524/3090
  Fax +31 (0)20 566 9206
  Email S.Mastenbroek@amc.uva.nl
Sponsor Academic Medical Center (AMC) (The Netherlands)
  Address Postbus 22660
  City/town Amsterdam
  Zip/Postcode 1100 DD
  Country Netherlands
  Sponsor website: http://www.amc.uva.nl/
Date applied 12/09/2005
Last edited 20/10/2008
Date ISRCTN assigned 12/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central